


APPENDIX

Claims 1, 3, 5, 6, and 7 (each once amended) and claims 9, 10, and 11 (new) are set forth below in marked-up form to aid the Examiner in identifying amendments to the claims. Additions are underlined, and deletions are shown with bold square brackets and strikethrough text [~~like this~~].

1. (Once Amended) An amide derivative represented by the [following] general formula (I):



[$\{\}$] in the formula, each of the symbols means as follows:

ring B[:] is a heteroaryl group which [may be] is unsubstituted or substituted and [may be] is optionally fused with a benzene ring;

X[:] is a bond, or a lower alkylene or an alkenylene, both of which [may be] are unsubstituted or substituted with hydroxy or a lower alkyl group, or X is a carbonyl[.] or a group represented by -NH-, [.] and when X is a lower alkylene [group] which [may be] is substituted with a lower alkyl group, [the hydrogen atoms bonded to the] a carbon atom [constituting] of the ring B [may form a lower alkylene group together] optionally bonds with the lower alkyl group so that a ring is formed[.]);

A[:] is a lower alkylene or a group represented by -lower alkylene-O-;


R^{1a}, R^{1b}[: they may be] are the same or different and each is a hydrogen atom or a lower alkyl group;

R²[:] is a hydrogen atom or a halogen atom; and

Z[:] is a nitrogen atom or a group represented by =CH-[]];
or a salt thereof.

3. (Once Amended) The amide derivative or the salt thereof according to claim 2, wherein the ring B is a heteroaryl group which [may be] is substituted with a substituent [selected] chosen from a halogen atom, lower alkyl, lower alkenyl, lower alkynyl, hydroxy, sulfanyl, halogeno lower alkyl, lower alkyl-O-, lower alkyl-S-, lower alkyl-O-CO-, carboxy, sulfonyl, sulfinyl, lower alkyl-SO-, lower alkyl-SO₂-, lower alkyl-CO-, lower alkyl-CO-O-, carbamoyl, lower alkyl-NH-CO-, di-lower alkyl-N-CO-, nitro, cyano, amino, lower alkyl-NH-, di-lower alkyl-N-, aryl-lower alkyl, halogeno aryl-lower alkyl, guanidino, lower alkyl-CO-NH, and lower alkyl-SO₂-NH-.

5. (Once Amended) An amide derivative represented by the [following] general formula (la):



[:] in the formula, each of the symbols means as follows:

ring B[:] is a heteroaryl group;
X[:] is a bond or a lower alkylene group;
R[:] is a hydrogen atom, a halogen atom, a lower alkyl group, amino group, an aryl lower alkyl group, or a halogeno aryl-lower alkyl group[:];
or a salt thereof.

6. (Once Amended)

(R)-4'-[2-[(2-Hydroxy-2-phenylethyl)amino]ethyl]-2-pyridinecarboxyanilide,
(R)-2-[1-(4-chlorobenzyl)-1H-imidazol-2-yl]-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide, (R)-2-[1-(3,4-dichlorobenzyl)-1H-tetrazol-5-yl]- 4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide,
(R)-2-(2-aminothiazol-4-yl)-4'-[2-(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide,
(R)-2-(2-benzyl-1H-1,2,4-triazol-3-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)-amino]ethyl]acetanilide,
(R)-2-(2-aminopyridin-6-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide, (R)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-2-(2-pyridyl)acetanilide,
(R)-4'-[2-[(2-hydroxy-2-phenylethyl)-amino]ethyl]-2-(2-pyrazinyl)acetanilide, (R)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-2-(2-pyrimidinyl)-acetanilide, ~~[and salts thereof]~~ or a salt of any of the foregoing.

7. (Once Amended) A ~~[pharmaceutical agent]~~ composition comprising ~~[the]~~ at least one amide derivative or the salt thereof ~~[according to]~~ as claimed in one of claims 1 through 6 in a pharmaceutically acceptable carrier.

9. (New) The composition as claimed in claim 7, wherein the amount of at least one amide derivative or the salt thereof is an amount effective for the treating diabetes mellitus in a human or animal patient in need of such treating.
10. (New) The amide derivative of general formula (I) as claimed in claim 1, wherein the amide derivative is an optical isomer, a hydrate, or a solvate of the amide derivative.
11. (New) A composition comprising an amide derivative of general formula (I) as claimed in claim 1 in a pharmaceutically acceptable carrier, wherein the amide derivative is present as a polymorphic substance.
12. (New) A method for treating diabetes mellitus in a human or animal patient in need of such treatment comprising administering to the patient an amount of an amide derivative of general formula (I) as claimed in claim 1, wherein the amount is an amount effective for such treatment.
13. (New) A method for treating obesity in a human or animal patient in need of such treatment comprising administering to the patient an amount of an amide derivative of general formula (I) as claimed in claim 1, wherein the amount is an amount effective for such treatment.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000